speb/financial-data huggingface dataset:
DNA balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 61522000.00
DNA balance_sheet (quarterly, 2025-09-30) — Gross PPE: 726867000.00
DNA income_statement (quarterly, 2025-09-30) — Gross Profit: 26035000.00
DNA income_statement (quarterly, 2025-09-30) — Impairment Of Capital Assets: 0.00
DNA income_statement (quarterly, 2025-09-30) — Interest Income: 5742000.00
DNA income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 5742000.00
DNA balance_sheet (quarterly, 2025-09-30) — Invested Capital: 559783000.00
DNA cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -72816000.00
DNA balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 13202000.00
DNA balance_sheet (quarterly, 2025-09-30) — Investments And Advances: 29891000.00
DNA balance_sheet (quarterly, 2025-09-30) — Land And Improvements: 6060000.00
DNA balance_sheet (quarterly, 2025-09-30) — Leases: 140511000.00
DNA balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 422870000.00
DNA balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 422870000.00
DNA cash_flow (quarterly, 2025-09-30) — Long Term Debt Payments: -24000.00
DNA balance_sheet (quarterly, 2025-09-30) — Machinery Furniture Equipment: 15684000.00
DNA cash_flow (quarterly, 2025-09-30) — Net Business Purchase And Sale: 0.00
DNA income_statement (quarterly, 2025-09-30) — Net Income: -80755000.00
DNA income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -80755000.00
DNA income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -80755000.00
DNA income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -80755000.00
DNA income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -80755000.00
DNA cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: -80755000.00
DNA income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -80755000.00
DNA income_statement (quarterly, 2025-09-30) — Net Interest Income: 5742000.00
DNA cash_flow (quarterly, 2025-09-30) — Net Investment Purchase And Sale: -73065000.00
DNA cash_flow (quarterly, 2025-09-30) — Net Issuance Payments Of Debt: -24000.00
DNA cash_flow (quarterly, 2025-09-30) — Net Long Term Debt Issuance: -24000.00
DNA income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: 5742000.00
DNA cash_flow (quarterly, 2025-09-30) — Net Other Investing Changes: 249000.00
DNA balance_sheet (quarterly, 2025-09-30) — Net PPE: 544792000.00
DNA cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: 0.00
DNA balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 498261000.00
DNA balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Liabilities: 74072000.00
DNA balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Revenue: 74072000.00
DNA income_statement (quarterly, 2025-09-30) — Normalized EBITDA: -76043000.00
DNA income_statement (quarterly, 2025-09-30) — Normalized Income: -82286810.00
DNA cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: -31606000.00
DNA cash_flow (quarterly, 2025-09-30) — Operating Gains Losses: -3683000.00
DNA income_statement (quarterly, 2025-09-30) — Operating Income: -88272000.00
DNA income_statement (quarterly, 2025-09-30) — Operating Revenue: 38837000.00
DNA balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 56836246.00
DNA balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 21861000.00
DNA balance_sheet (quarterly, 2025-09-30) — Other Equity Adjustments: 1996000.00
DNA income_statement (quarterly, 2025-09-30) — Other Gand A: 44954000.00
DNA income_statement (quarterly, 2025-09-30) — Other Income Expense: 1776000.00
DNA balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 61522000.00
DNA balance_sheet (quarterly, 2025-09-30) — Other Investments: 16689000.00
DNA cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: 9548000.00
DNA balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 46594000.00
DNA balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 17159000.00
DNA income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: -163000.00
DNA balance_sheet (quarterly, 2025-09-30) — Other Properties: 514852000.00
DNA balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 350797000.00
DNA income_statement (quarterly, 2025-09-30) — Otherunder Preferred Stock Dividend: 0.00
DNA balance_sheet (quarterly, 2025-09-30) — Payables: 10704000.00
DNA balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 90045000.00
DNA balance_sheet (quarterly, 2025-09-30) — Preferred Stock: 0.00
DNA income_statement (quarterly, 2025-09-30) — Pretax Income: -80754000.00
DNA cash_flow (quarterly, 2025-09-30) — Proceeds From Stock Option Exercised: 0.00
DNA balance_sheet (quarterly, 2025-09-30) — Properties: 0.00
DNA cash_flow (quarterly, 2025-09-30) — Purchase Of Business: 0.00
DNA cash_flow (quarterly, 2025-09-30) — Purchase Of Investment: -81706000.00
DNA cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: 0.00
DNA balance_sheet (quarterly, 2025-09-30) — Receivables: 22359000.00
DNA income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 12802000.00
DNA income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 14168000.00
DNA cash_flow (quarterly, 2025-09-30) — Repayment Of Debt: -24000.00
DNA income_statement (quarterly, 2025-09-30) — Research And Development: 69353000.00
DNA income_statement (quarterly, 2025-09-30) — Restructuring And Mergern Acquisition: 1745000.00
DNA balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -6069569000.00
DNA cash_flow (quarterly, 2025-09-30) — Sale Of Investment: 8641000.00
DNA income_statement (quarterly, 2025-09-30) — Selling General And Administration: 44954000.00
DNA balance_sheet (quarterly, 2025-09-30) — Share Issued: 56836246.00
DNA income_statement (quarterly, 2025-09-30) — Special Income Charges: -1745000.00
DNA cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 17841000.00
DNA balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 559783000.00
DNA balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 498261000.00
DNA income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 407190.00
DNA income_statement (quarterly, 2025-09-30) — Tax Provision: 1000.00
DNA income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.21
DNA balance_sheet (quarterly, 2025-09-30) — Total Assets: 1189165000.00
DNA balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 559783000.00
DNA balance_sheet (quarterly, 2025-09-30) — Total Debt: 422870000.00
DNA balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 559783000.00
DNA income_statement (quarterly, 2025-09-30) — Total Expenses: 127109000.00
DNA balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 629382000.00
DNA balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 683083000.00
DNA balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 514101000.00
DNA income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: -90017000.00
DNA income_statement (quarterly, 2025-09-30) — Total Unusual Items: 1939000.00
DNA income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 1939000.00
DNA balance_sheet (quarterly, 2025-09-30) — Working Capital: 390801000.00
DNA income_statement (quarterly, 2025-09-30) — Write Off: 0.00
DNA income_statement (annual, 2025-12-31) — +Operating Expense: 427063000.00
DNA income_statement (quarterly, 2025-12-31) — +Operating Expense: 96141000.00
DNA income_statement (annual, 2025-12-31) — +Total Revenue: 170155000.00
DNA income_statement (quarterly, 2025-12-31) — +Total Revenue: 33396000.00
DNA balance_sheet (annual, 2025-12-31) — Accounts Payable: 10566000.00
DNA balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 10566000.00
DNA balance_sheet (annual, 2025-12-31) — Accounts Receivable: 24026000.00
DNA balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 24026000.00
DNA balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -190597000.00
DNA balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -190597000.00
DNA balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 6657053000.00
DNA balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 6657053000.00
DNA cash_flow (annual, 2025-12-31) — Amortization Of Securities: -3390000.00
DNA cash_flow (quarterly, 2025-12-31) — Amortization Of Securities: -888000.00
DNA cash_flow (annual, 2025-12-31) — Asset Impairment Charge: 0.00
DNA cash_flow (quarterly, 2025-12-31) — Asset Impairment Charge: 0.00
DNA balance_sheet (annual, 2025-12-31) — Available For Sale Securities: 12687000.00
DNA balance_sheet (quarterly, 2025-12-31) — Available For Sale Securities: 12687000.00
DNA income_statement (annual, 2025-12-31) — Basic Average Shares: 55457676.00
DNA income_statement (annual, 2025-12-31) — Basic EPS: -5.64
DNA cash_flow (annual, 2025-12-31) — Beginning Cash Position: 605743000.00
DNA cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 156960000.00
DNA balance_sheet (annual, 2025-12-31) — Buildings And Improvements: 49760000.00
DNA balance_sheet (quarterly, 2025-12-31) — Buildings And Improvements: 49760000.00
DNA cash_flow (annual, 2025-12-31) — Capital Expenditure: -7665000.00
DNA cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -5000.00
DNA balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 439885000.00
DNA balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 439885000.00
DNA balance_sheet (annual, 2025-12-31) — Capital Stock: 6000.00
DNA balance_sheet (quarterly, 2025-12-31) — Capital Stock: 6000.00
DNA balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 167202000.00
DNA balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 167202000.00
DNA balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 422620000.00
DNA balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 422620000.00
DNA cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: 17775000.00
DNA cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: 8142000.00
DNA cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: -240289000.00
DNA cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: 95099000.00
DNA cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: -171059000.00
DNA cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: -47678000.00
DNA cash_flow (annual, 2025-12-31) — Change In Account Payable: -2992000.00
DNA cash_flow (quarterly, 2025-12-31) — Change In Account Payable: -19983000.00
DNA cash_flow (annual, 2025-12-31) — Change In Accrued Expense: 10376000.00
DNA cash_flow (annual, 2025-12-31) — Change In Other Current Assets: 4110000.00
DNA cash_flow (quarterly, 2025-12-31) — Change In Other Current Assets: 334000.00
DNA cash_flow (annual, 2025-12-31) — Change In Other Current Liabilities: -16469000.00
DNA cash_flow (quarterly, 2025-12-31) — Change In Other Current Liabilities: -2135000.00
DNA cash_flow (annual, 2025-12-31) — Change In Other Working Capital: -32393000.00
DNA cash_flow (quarterly, 2025-12-31) — Change In Other Working Capital: -5184000.00
DNA cash_flow (annual, 2025-12-31) — Change In Payable: -2992000.00
DNA cash_flow (quarterly, 2025-12-31) — Change In Payable: -19983000.00
DNA cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: 7384000.00
DNA cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: -9607000.00
DNA cash_flow (annual, 2025-12-31) — Change In Prepaid Assets: -5247000.00
DNA cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: -5177000.00
DNA cash_flow (annual, 2025-12-31) — Change In Receivables: -1473000.00
DNA cash_flow (quarterly, 2025-12-31) — Change In Receivables: -1818000.00
DNA cash_flow (annual, 2025-12-31) — Change In Working Capital: -44088000.00
DNA cash_flow (quarterly, 2025-12-31) — Change In Working Capital: -23587000.00
DNA cash_flow (annual, 2025-12-31) — Changes In Account Receivables: -1473000.00
DNA cash_flow (quarterly, 2025-12-31) — Changes In Account Receivables: -1818000.00
DNA cash_flow (annual, 2025-12-31) — Changes In Cash: -393573000.00
DNA cash_flow (quarterly, 2025-12-31) — Changes In Cash: 55563000.00
DNA balance_sheet (annual, 2025-12-31) — Common Stock: 6000.00
DNA balance_sheet (quarterly, 2025-12-31) — Common Stock: 6000.00
DNA balance_sheet (annual, 2025-12-31) — Common Stock Equity: 508590000.00
DNA balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 508590000.00
DNA cash_flow (annual, 2025-12-31) — Common Stock Issuance: 19469000.00
DNA cash_flow (quarterly, 2025-12-31) — Common Stock Issuance: 9152000.00
DNA balance_sheet (annual, 2025-12-31) — Construction In Progress: 192000.00
DNA balance_sheet (quarterly, 2025-12-31) — Construction In Progress: 192000.00
DNA income_statement (annual, 2025-12-31) — Cost Of Revenue: 46972000.00
DNA income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 7301000.00
DNA balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 10496000.00
DNA balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 10496000.00
DNA balance_sheet (annual, 2025-12-31) — Current Assets: 471838000.00
DNA balance_sheet (quarterly, 2025-12-31) — Current Assets: 471838000.00
DNA balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 22807000.00
DNA balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 22807000.00
DNA balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 22807000.00
DNA balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 22807000.00
DNA balance_sheet (annual, 2025-12-31) — Current Deferred Liabilities: 19979000.00
DNA balance_sheet (quarterly, 2025-12-31) — Current Deferred Liabilities: 19979000.00
DNA balance_sheet (annual, 2025-12-31) — Current Deferred Revenue: 19979000.00
DNA balance_sheet (quarterly, 2025-12-31) — Current Deferred Revenue: 19979000.00
DNA balance_sheet (annual, 2025-12-31) — Current Liabilities: 95970000.00
DNA balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 95970000.00
DNA cash_flow (annual, 2025-12-31) — Deferred Income Tax: -1364000.00
DNA cash_flow (annual, 2025-12-31) — Deferred Tax: -1364000.00
DNA cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 58990000.00
DNA cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 13663000.00
DNA cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 58990000.00
DNA cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 13663000.00
DNA income_statement (annual, 2025-12-31) — Diluted Average Shares: 55457676.00
DNA income_statement (annual, 2025-12-31) — Diluted EPS: -5.64
DNA income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: -312763000.00
DNA income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -80751000.00
DNA balance_sheet (annual, 2025-12-31) — Duefrom Related Parties Current: 229000.00
DNA balance_sheet (quarterly, 2025-12-31) — Duefrom Related Parties Current: 229000.00
DNA income_statement (annual, 2025-12-31) — EBIT: -313600000.00
DNA income_statement (quarterly, 2025-12-31) — EBIT: -79766000.00
DNA income_statement (annual, 2025-12-31) — EBITDA: -254610000.00
DNA income_statement (quarterly, 2025-12-31) — EBITDA: -66103000.00
DNA income_statement (annual, 2025-12-31) — Earnings From Equity Interest: 0.00
DNA cash_flow (annual, 2025-12-31) — Earnings Losses From Equity Investments: 0.00
DNA cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: 201000.00
DNA cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: -152000.00
DNA cash_flow (annual, 2025-12-31) — End Cash Position: 212371000.00
DNA cash_flow (quarterly, 2025-12-31) — End Cash Position: 212371000.00
DNA balance_sheet (annual, 2025-12-31) — Financial Assets: 191000.00
DNA balance_sheet (quarterly, 2025-12-31) — Financial Assets: 191000.00
DNA cash_flow (annual, 2025-12-31) — Financing Cash Flow: 17775000.00
DNA cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: 8142000.00
DNA cash_flow (annual, 2025-12-31) — Free Cash Flow: -178724000.00
DNA cash_flow (quarterly, 2025-12-31) — Free Cash Flow: -47683000.00
DNA cash_flow (annual, 2025-12-31) — Gain Loss On Investment Securities: 16411000.00
DNA cash_flow (quarterly, 2025-12-31) — Gain Loss On Investment Securities: 16136000.00
DNA cash_flow (annual, 2025-12-31) — Gain Loss On Sale Of Business: 0.00
DNA cash_flow (quarterly, 2025-12-31) — Gain Loss On Sale Of Business: 0.00
DNA cash_flow (annual, 2025-12-31) — Gain Loss On Sale Of PPE: 0.00
DNA income_statement (annual, 2025-12-31) — Gain On Sale Of Business: 0.00
DNA income_statement (quarterly, 2025-12-31) — Gain On Sale Of Business: 0.00
DNA income_statement (annual, 2025-12-31) — Gain On Sale Of Security: -16411000.00
DNA income_statement (quarterly, 2025-12-31) — Gain On Sale Of Security: -18017000.00
DNA balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 1851000.00
DNA balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 1851000.00
DNA income_statement (annual, 2025-12-31) — General And Administrative Expense: 183290000.00
DNA income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 46014000.00
DNA balance_sheet (annual, 2025-12-31) — Goodwill And Other Intangible Assets: 56924000.00
DNA balance_sheet (quarterly, 2025-12-31) — Goodwill And Other Intangible Assets: 56924000.00
DNA balance_sheet (annual, 2025-12-31) — Gross PPE: 719298000.00
DNA balance_sheet (quarterly, 2025-12-31) — Gross PPE: 719298000.00
DNA income_statement (annual, 2025-12-31) — Gross Profit: 123183000.00
DNA income_statement (quarterly, 2025-12-31) — Gross Profit: 26095000.00
DNA income_statement (annual, 2025-12-31) — Impairment Of Capital Assets: 0.00
DNA income_statement (quarterly, 2025-12-31) — Impairment Of Capital Assets: 0.00
DNA cash_flow (annual, 2025-12-31) — Income Tax Paid Supplemental Data: 192000.00
DNA income_statement (annual, 2025-12-31) — Interest Expense: 0.00
DNA income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 0.00
DNA income_statement (annual, 2025-12-31) — Interest Income: 22616000.00
DNA income_statement (quarterly, 2025-12-31) — Interest Income: 4710000.00
DNA income_statement (annual, 2025-12-31) — Interest Income Non Operating: 22616000.00
DNA income_statement (quarterly, 2025-12-31) — Interest Income Non Operating: 4710000.00
DNA cash_flow (annual, 2025-12-31) — Interest Paid Supplemental Data: 4000.00
DNA balance_sheet (annual, 2025-12-31) — Invested Capital: 508590000.00
DNA balance_sheet (quarterly, 2025-12-31) — Invested Capital: 508590000.00
DNA cash_flow (annual, 2025-12-31) — Investing Cash Flow: -240289000.00
DNA cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: 95099000.00
DNA balance_sheet (annual, 2025-12-31) — Investmentin Financial Assets: 12687000.00
DNA balance_sheet (quarterly, 2025-12-31) — Investmentin Financial Assets: 12687000.00
DNA balance_sheet (annual, 2025-12-31) — Investments And Advances: 14875000.00
DNA balance_sheet (quarterly, 2025-12-31) — Investments And Advances: 14875000.00
DNA cash_flow (annual, 2025-12-31) — Issuance Of Capital Stock: 19469000.00
DNA cash_flow (quarterly, 2025-12-31) — Issuance Of Capital Stock: 9152000.00
DNA balance_sheet (annual, 2025-12-31) — Land And Improvements: 6060000.00
DNA balance_sheet (quarterly, 2025-12-31) — Land And Improvements: 6060000.00
DNA balance_sheet (annual, 2025-12-31) — Leases: 140513000.00
DNA balance_sheet (quarterly, 2025-12-31) — Leases: 140513000.00
DNA balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 417078000.00
DNA balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 417078000.00
DNA balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 417078000.00
DNA balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 417078000.00
DNA cash_flow (annual, 2025-12-31) — Long Term Debt Payments: -354000.00
DNA cash_flow (quarterly, 2025-12-31) — Long Term Debt Payments: -25000.00
DNA balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 15576000.00
DNA balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 15576000.00
DNA cash_flow (annual, 2025-12-31) — Net Business Purchase And Sale: 0.00
DNA cash_flow (quarterly, 2025-12-31) — Net Business Purchase And Sale: 0.00
DNA cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: 19469000.00
DNA cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: 9152000.00
DNA income_statement (annual, 2025-12-31) — Net Income: -312763000.00
DNA income_statement (quarterly, 2025-12-31) — Net Income: -80751000.00
DNA income_statement (annual, 2025-12-31) — Net Income Common Stockholders: -312763000.00
DNA income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -80751000.00
DNA income_statement (annual, 2025-12-31) — Net Income Continuous Operations: -312763000.00
DNA income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -80751000.00
DNA income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -312763000.00
DNA income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -80751000.00
DNA income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -312763000.00
DNA income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -80751000.00
DNA cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: -312763000.00
DNA cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: -80751000.00
DNA income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: -312763000.00
DNA income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -80751000.00
DNA income_statement (annual, 2025-12-31) — Net Interest Income: 22616000.00
DNA income_statement (quarterly, 2025-12-31) — Net Interest Income: 4710000.00
DNA cash_flow (annual, 2025-12-31) — Net Investment Purchase And Sale: -233248000.00
DNA cash_flow (quarterly, 2025-12-31) — Net Investment Purchase And Sale: 94991000.00
DNA cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: -354000.00
DNA cash_flow (quarterly, 2025-12-31) — Net Issuance Payments Of Debt: -25000.00
DNA cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: -354000.00
DNA cash_flow (quarterly, 2025-12-31) — Net Long Term Debt Issuance: -25000.00
DNA income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: 22616000.00
DNA income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: 4710000.00
DNA cash_flow (annual, 2025-12-31) — Net Other Financing Charges: -1340000.00
DNA cash_flow (quarterly, 2025-12-31) — Net Other Financing Charges: -985000.00
DNA cash_flow (annual, 2025-12-31) — Net Other Investing Changes: 50000.00
DNA cash_flow (quarterly, 2025-12-31) — Net Other Investing Changes: -461000.00
DNA balance_sheet (annual, 2025-12-31) — Net PPE: 528701000.00
DNA balance_sheet (quarterly, 2025-12-31) — Net PPE: 528701000.00
DNA cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -7091000.00
DNA cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: 569000.00
DNA balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 451666000.00
DNA balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 451666000.00
DNA balance_sheet (annual, 2025-12-31) — Non Current Deferred Liabilities: 75182000.00
DNA balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Liabilities: 75182000.00
DNA balance_sheet (annual, 2025-12-31) — Non Current Deferred Revenue: 75182000.00
DNA balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Revenue: 75182000.00
DNA income_statement (annual, 2025-12-31) — Normalized EBITDA: -226801000.00
DNA income_statement (quarterly, 2025-12-31) — Normalized EBITDA: -49224000.00
DNA income_statement (annual, 2025-12-31) — Normalized Income: -285037427.00
DNA income_statement (quarterly, 2025-12-31) — Normalized Income: -64005341.49
DNA cash_flow (annual, 2025-12-31) — Operating Cash Flow: -171059000.00
DNA cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: -47678000.00
DNA cash_flow (annual, 2025-12-31) — Operating Gains Losses: 16411000.00
DNA cash_flow (quarterly, 2025-12-31) — Operating Gains Losses: 16136000.00
DNA income_statement (annual, 2025-12-31) — Operating Income: -303880000.00
DNA income_statement (quarterly, 2025-12-31) — Operating Income: -70046000.00
DNA income_statement (annual, 2025-12-31) — Operating Revenue: 170155000.00
DNA income_statement (quarterly, 2025-12-31) — Operating Revenue: 33396000.00
DNA balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 58207298.00
DNA balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 58207298.00
DNA balance_sheet (annual, 2025-12-31) — Other Current Assets: 24963000.00
DNA balance_sheet (quarterly, 2025-12-31) — Other Current Assets: 24963000.00
DNA balance_sheet (annual, 2025-12-31) — Other Current Liabilities: 27048000.00
DNA balance_sheet (quarterly, 2025-12-31) — Other Current Liabilities: 27048000.00
DNA balance_sheet (annual, 2025-12-31) — Other Equity Adjustments: 1851000.00
DNA balance_sheet (quarterly, 2025-12-31) — Other Equity Adjustments: 1851000.00
DNA income_statement (annual, 2025-12-31) — Other Gand A: 183290000.00
DNA income_statement (quarterly, 2025-12-31) — Other Gand A: 46014000.00
DNA income_statement (annual, 2025-12-31) — Other Income Expense: -32336000.00
DNA income_statement (quarterly, 2025-12-31) — Other Income Expense: -16058000.00
DNA balance_sheet (annual, 2025-12-31) — Other Intangible Assets: 56924000.00
DNA balance_sheet (quarterly, 2025-12-31) — Other Intangible Assets: 56924000.00
DNA balance_sheet (annual, 2025-12-31) — Other Investments: 2188000.00
DNA balance_sheet (quarterly, 2025-12-31) — Other Investments: 2188000.00
DNA cash_flow (annual, 2025-12-31) — Other Non Cash Items: 33599000.00
DNA cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: 8086000.00
DNA balance_sheet (annual, 2025-12-31) — Other Non Current Assets: 47167000.00
DNA balance_sheet (quarterly, 2025-12-31) — Other Non Current Assets: 47167000.00
DNA balance_sheet (annual, 2025-12-31) — Other Non Current Liabilities: 22876000.00
DNA balance_sheet (quarterly, 2025-12-31) — Other Non Current Liabilities: 22876000.00
DNA income_statement (annual, 2025-12-31) — Other Non Operating Income Expenses: -4527000.00
DNA income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 821000.00
DNA balance_sheet (annual, 2025-12-31) — Other Properties: 507197000.00
DNA balance_sheet (quarterly, 2025-12-31) — Other Properties: 507197000.00
DNA balance_sheet (annual, 2025-12-31) — Other Short Term Investments: 255418000.00
DNA balance_sheet (quarterly, 2025-12-31) — Other Short Term Investments: 255418000.00
DNA balance_sheet (annual, 2025-12-31) — Payables: 10566000.00
DNA balance_sheet (quarterly, 2025-12-31) — Payables: 10566000.00
DNA balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 21062000.00
DNA balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 21062000.00
DNA balance_sheet (annual, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 5074000.00
DNA balance_sheet (quarterly, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 5074000.00
DNA balance_sheet (annual, 2025-12-31) — Preferred Stock: 0.00
DNA balance_sheet (quarterly, 2025-12-31) — Preferred Stock: 0.00
DNA income_statement (annual, 2025-12-31) — Pretax Income: -313600000.00
DNA income_statement (quarterly, 2025-12-31) — Pretax Income: -81394000.00
DNA cash_flow (annual, 2025-12-31) — Proceeds From Stock Option Exercised: 0.00
DNA cash_flow (quarterly, 2025-12-31) — Proceeds From Stock Option Exercised: 0.00
DNA balance_sheet (annual, 2025-12-31) — Properties: 0.00
DNA balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
DNA cash_flow (annual, 2025-12-31) — Purchase Of Business: 0.00
DNA cash_flow (quarterly, 2025-12-31) — Purchase Of Business: 0.00
DNA cash_flow (annual, 2025-12-31) — Purchase Of Investment: -418630000.00
DNA cash_flow (quarterly, 2025-12-31) — Purchase Of Investment: -16792000.00
DNA cash_flow (annual, 2025-12-31) — Purchase Of PPE: -7665000.00
DNA cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: -5000.00
DNA balance_sheet (annual, 2025-12-31) — Receivables: 24255000.00
DNA balance_sheet (quarterly, 2025-12-31) — Receivables: 24255000.00
DNA income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 46972000.00
DNA income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 7301000.00
DNA income_statement (annual, 2025-12-31) — Reconciled Depreciation: 58990000.00
DNA income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 13663000.00
DNA cash_flow (annual, 2025-12-31) — Repayment Of Debt: -354000.00
DNA cash_flow (quarterly, 2025-12-31) — Repayment Of Debt: -25000.00
DNA income_statement (annual, 2025-12-31) — Research And Development: 243773000.00
DNA income_statement (quarterly, 2025-12-31) — Research And Development: 50127000.00
DNA income_statement (annual, 2025-12-31) — Restructuring And Mergern Acquisition: 11398000.00
DNA income_statement (quarterly, 2025-12-31) — Restructuring And Mergern Acquisition: 706000.00
DNA balance_sheet (annual, 2025-12-31) — Retained Earnings: -6150320000.00
DNA balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -6150320000.00
DNA cash_flow (annual, 2025-12-31) — Sale Of Investment: 185382000.00
DNA cash_flow (quarterly, 2025-12-31) — Sale Of Investment: 111783000.00
DNA cash_flow (annual, 2025-12-31) — Sale Of PPE: 574000.00
DNA cash_flow (quarterly, 2025-12-31) — Sale Of PPE: 574000.00
DNA income_statement (annual, 2025-12-31) — Selling General And Administration: 183290000.00
DNA income_statement (quarterly, 2025-12-31) — Selling General And Administration: 46014000.00
DNA balance_sheet (annual, 2025-12-31) — Share Issued: 58207298.00
DNA balance_sheet (quarterly, 2025-12-31) — Share Issued: 58207298.00
DNA income_statement (annual, 2025-12-31) — Special Income Charges: -11398000.00
DNA income_statement (quarterly, 2025-12-31) — Special Income Charges: 1138000.00
DNA cash_flow (annual, 2025-12-31) — Stock Based Compensation: 81546000.00
DNA cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 21027000.00
DNA balance_sheet (annual, 2025-12-31) — Stockholders Equity: 508590000.00
DNA balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 508590000.00
DNA balance_sheet (annual, 2025-12-31) — Tangible Book Value: 451666000.00
DNA balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 451666000.00
DNA income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: -83427.00
DNA income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -133341.49
DNA income_statement (annual, 2025-12-31) — Tax Provision: -837000.00
DNA income_statement (quarterly, 2025-12-31) — Tax Provision: -643000.00
DNA income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.00
DNA income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.01
DNA balance_sheet (annual, 2025-12-31) — Total Assets: 1119696000.00
DNA balance_sheet (quarterly, 2025-12-31) — Total Assets: 1119696000.00
DNA balance_sheet (annual, 2025-12-31) — Total Capitalization: 508590000.00
DNA balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 508590000.00
DNA balance_sheet (annual, 2025-12-31) — Total Debt: 439885000.00
DNA balance_sheet (quarterly, 2025-12-31) — Total Debt: 439885000.00
DNA balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 508590000.00
DNA balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 508590000.00
DNA income_statement (annual, 2025-12-31) — Total Expenses: 474035000.00
DNA income_statement (quarterly, 2025-12-31) — Total Expenses: 103442000.00
DNA balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 611106000.00
DNA balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 611106000.00
DNA balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 647858000.00
DNA balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 647858000.00
DNA balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 515136000.00
DNA balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 515136000.00
DNA income_statement (annual, 2025-12-31) — Total Operating Income As Reported: -315278000.00
DNA income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: -70752000.00
DNA income_statement (annual, 2025-12-31) — Total Unusual Items: -27809000.00
DNA income_statement (quarterly, 2025-12-31) — Total Unusual Items: -16879000.00
DNA income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: -27809000.00
DNA income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -16879000.00
DNA balance_sheet (annual, 2025-12-31) — Working Capital: 375868000.00
DNA balance_sheet (quarterly, 2025-12-31) — Working Capital: 375868000.00
DNA income_statement (quarterly, 2026-03-31) — +Operating Expense: 87750000.00
DNA income_statement (quarterly, 2026-03-31) — +Total Revenue: 19474000.00
DNA balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 16309000.00
DNA balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 19815000.00
DNA balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -189376000.00
DNA balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 6674860000.00
DNA cash_flow (quarterly, 2026-03-31) — Amortization Of Securities: -120000.00
DNA balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 12411000.00
DNA income_statement (quarterly, 2026-03-31) — Basic Average Shares: 59563454.00
DNA income_statement (quarterly, 2026-03-31) — Basic EPS: -1.39
DNA cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 212371000.00
DNA balance_sheet (quarterly, 2026-03-31) — Buildings And Improvements: 49760000.00
DNA cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -1933000.00
DNA balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 410700000.00
DNA balance_sheet (quarterly, 2026-03-31) — Capital Stock: 6000.00
DNA balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 143864000.00
DNA balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 373456000.00
DNA cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: -19000.00
DNA cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: 23132000.00
DNA cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: -46433000.00
DNA cash_flow (quarterly, 2026-03-31) — Change In Other Current Assets: 94000.00
DNA cash_flow (quarterly, 2026-03-31) — Change In Other Current Liabilities: -5753000.00
DNA cash_flow (quarterly, 2026-03-31) — Change In Other Working Capital: -2606000.00
DNA cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: -11601000.00
DNA cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: 5930000.00
DNA cash_flow (quarterly, 2026-03-31) — Change In Receivables: -242000.00
DNA cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -14178000.00
DNA cash_flow (quarterly, 2026-03-31) — Changes In Account Receivables: -242000.00
DNA cash_flow (quarterly, 2026-03-31) — Changes In Cash: -23573000.00
DNA balance_sheet (quarterly, 2026-03-31) — Common Stock: 6000.00
DNA balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 443153000.00
DNA balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 4453000.00
DNA income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 3098000.00
DNA balance_sheet (quarterly, 2026-03-31) — Current Accrued Expenses: 48376000.00
DNA balance_sheet (quarterly, 2026-03-31) — Current Assets: 409955000.00
DNA balance_sheet (quarterly, 2026-03-31) — Current Deferred Liabilities: 14910000.00
DNA balance_sheet (quarterly, 2026-03-31) — Current Deferred Revenue: 14910000.00
DNA balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 79595000.00
DNA cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 12799000.00
DNA cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 12799000.00
DNA income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 59563454.00
DNA income_statement (quarterly, 2026-03-31) — Diluted EPS: -1.39
DNA income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -82587000.00
DNA balance_sheet (quarterly, 2026-03-31) — Duefrom Related Parties Current: 454000.00
DNA income_statement (quarterly, 2026-03-31) — EBIT: -71374000.00
DNA income_statement (quarterly, 2026-03-31) — EBITDA: -58575000.00
DNA cash_flow (quarterly, 2026-03-31) — Effect Of Exchange Rate Changes: -129000.00
DNA cash_flow (quarterly, 2026-03-31) — End Cash Position: 188669000.00
DNA balance_sheet (quarterly, 2026-03-31) — Financial Assets: 104000.00
DNA cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: -19000.00
DNA cash_flow (quarterly, 2026-03-31) — Free Cash Flow: -48619000.00
DNA cash_flow (quarterly, 2026-03-31) — Gain Loss On Investment Securities: 1214000.00
DNA income_statement (quarterly, 2026-03-31) — Gain On Sale Of Security: -1214000.00
DNA balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: 1194000.00
DNA income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 37830000.00
DNA balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 48860000.00
DNA balance_sheet (quarterly, 2026-03-31) — Gross PPE: 706200000.00
DNA income_statement (quarterly, 2026-03-31) — Gross Profit: 16376000.00
DNA income_statement (quarterly, 2026-03-31) — Interest Income: 3596000.00
DNA income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 3596000.00
DNA balance_sheet (quarterly, 2026-03-31) — Invested Capital: 443153000.00
DNA cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: 23132000.00
DNA balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 12411000.00
DNA balance_sheet (quarterly, 2026-03-31) — Investments And Advances: 14599000.00
DNA balance_sheet (quarterly, 2026-03-31) — Land And Improvements: 6060000.00
DNA balance_sheet (quarterly, 2026-03-31) — Leases: 138289000.00
DNA balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 410700000.00
DNA balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 410700000.00
DNA cash_flow (quarterly, 2026-03-31) — Long Term Debt Payments: -19000.00
DNA balance_sheet (quarterly, 2026-03-31) — Machinery Furniture Equipment: 13153000.00
DNA income_statement (quarterly, 2026-03-31) — Net Income: -82587000.00
DNA income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -82587000.00
DNA income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -76059000.00
DNA income_statement (quarterly, 2026-03-31) — Net Income Discontinuous Operations: -6528000.00
DNA income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -82587000.00
DNA income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -76059000.00
DNA cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -76059000.00
DNA income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -82587000.00
DNA income_statement (quarterly, 2026-03-31) — Net Interest Income: 3596000.00
DNA cash_flow (quarterly, 2026-03-31) — Net Investment Purchase And Sale: 25017000.00
DNA cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: -19000.00
DNA cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: -19000.00
DNA income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: 3596000.00
DNA cash_flow (quarterly, 2026-03-31) — Net Other Investing Changes: 48000.00
DNA balance_sheet (quarterly, 2026-03-31) — Net PPE: 516824000.00
DNA cash_flow (quarterly, 2026-03-31) — Net PPE Purchase And Sale: -1933000.00
DNA balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 394293000.00
DNA balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Liabilities: 77895000.00
DNA balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Revenue: 77895000.00
DNA income_statement (quarterly, 2026-03-31) — Normalized EBITDA: -57361000.00
DNA income_statement (quarterly, 2026-03-31) — Normalized Income: -74846275.56
DNA cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: -46686000.00
DNA cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: 1214000.00
DNA income_statement (quarterly, 2026-03-31) — Operating Income: -71374000.00
DNA income_statement (quarterly, 2026-03-31) — Operating Revenue: 19474000.00
DNA balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 58207298.00
DNA balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 16230000.00
DNA balance_sheet (quarterly, 2026-03-31) — Other Equity Adjustments: 1194000.00
DNA income_statement (quarterly, 2026-03-31) — Other Gand A: 37830000.00
DNA income_statement (quarterly, 2026-03-31) — Other Income Expense: -8361000.00
DNA balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 48860000.00
DNA balance_sheet (quarterly, 2026-03-31) — Other Investments: 2188000.00
DNA cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: 13805000.00
DNA balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 42733000.00
DNA balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 21732000.00
DNA income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: -7147000.00
DNA balance_sheet (quarterly, 2026-03-31) — Other Properties: 494485000.00
DNA balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 229592000.00
DNA balance_sheet (quarterly, 2026-03-31) — Payables: 16309000.00
DNA balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 64685000.00
DNA balance_sheet (quarterly, 2026-03-31) — Preferred Stock: 0.00
DNA income_statement (quarterly, 2026-03-31) — Pretax Income: -76139000.00
DNA balance_sheet (quarterly, 2026-03-31) — Properties: 0.00
DNA cash_flow (quarterly, 2026-03-31) — Purchase Of Investment: -83161000.00
DNA cash_flow (quarterly, 2026-03-31) — Purchase Of PPE: -1933000.00
DNA balance_sheet (quarterly, 2026-03-31) — Receivables: 20269000.00
DNA income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 3098000.00
DNA income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 12799000.00
DNA cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: -19000.00
DNA income_statement (quarterly, 2026-03-31) — Research And Development: 49920000.00
DNA income_statement (quarterly, 2026-03-31) — Restructuring And Mergern Acquisition: 0.00
DNA balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -6232907000.00
DNA cash_flow (quarterly, 2026-03-31) — Sale Of Investment: 108178000.00
DNA income_statement (quarterly, 2026-03-31) — Selling General And Administration: 37830000.00
DNA balance_sheet (quarterly, 2026-03-31) — Share Issued: 58207298.00
DNA income_statement (quarterly, 2026-03-31) — Special Income Charges: 0.00
DNA cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 15853000.00
DNA balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 443153000.00
DNA balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 394293000.00
DNA income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: -1275.56
DNA income_statement (quarterly, 2026-03-31) — Tax Provision: -80000.00
DNA income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.00
DNA balance_sheet (quarterly, 2026-03-31) — Total Assets: 1033075000.00
DNA balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 443153000.00
DNA balance_sheet (quarterly, 2026-03-31) — Total Debt: 410700000.00
DNA balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 443153000.00
DNA income_statement (quarterly, 2026-03-31) — Total Expenses: 90848000.00
DNA balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 589922000.00
DNA balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 623120000.00
DNA balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 510327000.00
DNA income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: -71374000.00
DNA income_statement (quarterly, 2026-03-31) — Total Unusual Items: -1214000.00
DNA income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -1214000.00
DNA balance_sheet (quarterly, 2026-03-31) — Working Capital: 330360000.00
DNA income_statement (quarterly, 2026-03-31) — Write Off: 0.00
DNAMEDIA.NS income_statement (annual, 2022-03-31) — +Operating Expense: 141444000.00
DNAMEDIA.NS income_statement (annual, 2022-03-31) — +Total Revenue: 64829000.00
DNAMEDIA.NS balance_sheet (annual, 2022-03-31) — Accounts Payable: 43768000.00
DNAMEDIA.NS balance_sheet (annual, 2022-03-31) — Accounts Receivable: 127352000.00
DNAMEDIA.NS balance_sheet (annual, 2022-03-31) — Accumulated Depreciation: 0.00
DNAMEDIA.NS balance_sheet (annual, 2022-03-31) — Allowance For Doubtful Accounts Receivable: -41077000.00
DNAMEDIA.NS cash_flow (annual, 2022-03-31) — Amortization Cash Flow: 0.00
DNAMEDIA.NS balance_sheet (annual, 2022-03-31) — Assets Held For Sale Current: 0.00
DNAMEDIA.NS income_statement (annual, 2022-03-31) — Basic Average Shares: 117708018.00
DNAMEDIA.NS income_statement (annual, 2022-03-31) — Basic EPS: 2.03
DNAMEDIA.NS cash_flow (annual, 2022-03-31) — Beginning Cash Position: 293000.00
DNAMEDIA.NS balance_sheet (annual, 2022-03-31) — Capital Stock: 117708000.00
DNAMEDIA.NS balance_sheet (annual, 2022-03-31) — Cash And Cash Equivalents: 16766000.00
DNAMEDIA.NS balance_sheet (annual, 2022-03-31) — Cash Cash Equivalents And Short Term Investments: 16766000.00
DNAMEDIA.NS balance_sheet (annual, 2022-03-31) — Cash Equivalents: 0.00
DNAMEDIA.NS balance_sheet (annual, 2022-03-31) — Cash Financial: 16766000.00
DNAMEDIA.NS cash_flow (annual, 2022-03-31) — Change In Inventory: 0.00
DNAMEDIA.NS cash_flow (annual, 2022-03-31) — Change In Payable: -70052000.00
DNAMEDIA.NS cash_flow (annual, 2022-03-31) — Change In Receivables: -142431000.00
DNAMEDIA.NS cash_flow (annual, 2022-03-31) — Change In Working Capital: -212483000.00
DNAMEDIA.NS cash_flow (annual, 2022-03-31) — Changes In Cash: 16473000.00
DNAMEDIA.NS balance_sheet (annual, 2022-03-31) — Common Stock: 117708000.00
DNAMEDIA.NS balance_sheet (annual, 2022-03-31) — Common Stock Equity: -5549952000.00
DNAMEDIA.NS balance_sheet (annual, 2022-03-31) — Construction In Progress: 0.00
DNAMEDIA.NS income_statement (annual, 2022-03-31) — Cost Of Revenue: 0.00
DNAMEDIA.NS balance_sheet (annual, 2022-03-31) — Current Assets: 298117000.00
DNAMEDIA.NS balance_sheet (annual, 2022-03-31) — Current Debt: 0.00
DNAMEDIA.NS balance_sheet (annual, 2022-03-31) — Current Debt And Capital Lease Obligation: 0.00
DNAMEDIA.NS balance_sheet (annual, 2022-03-31) — Current Liabilities: 3233988000.00
DNAMEDIA.NS balance_sheet (annual, 2022-03-31) — Current Provisions: 100000.00
DNAMEDIA.NS cash_flow (annual, 2022-03-31) — Depreciation And Amortization: 0.00
DNAMEDIA.NS income_statement (annual, 2022-03-31) — Depreciation And Amortization In Income Statement: 0.00
DNAMEDIA.NS income_statement (annual, 2022-03-31) — Depreciation Income Statement: 0.00
DNAMEDIA.NS income_statement (annual, 2022-03-31) — Diluted Average Shares: 117708018.00
DNAMEDIA.NS income_statement (annual, 2022-03-31) — Diluted EPS: 2.03
DNAMEDIA.NS income_statement (annual, 2022-03-31) — Diluted NI Availto Com Stockholders: 239457000.00
DNAMEDIA.NS income_statement (annual, 2022-03-31) — EBIT: -76615000.00
DNAMEDIA.NS income_statement (annual, 2022-03-31) — EBITDA: -76615000.00
DNAMEDIA.NS cash_flow (annual, 2022-03-31) — End Cash Position: 16766000.00
DNAMEDIA.NS cash_flow (annual, 2022-03-31) — Financing Cash Flow: 0.00